Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

NCT05089916 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
EGFR Positive Non-small Cell Lung Cancer
Oligoprogression

Interventions

DRUG: Osimertinib
RADIATION: Radiotherapy

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]